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both polymorphisms (-6llA and -56C) was significantly 
higher in DNTM patients than in controls (OR=168 CI 
95%=2.1-132) or in PNTM patients (OR=9.3, CI 
95 % = l-l-78+1).The probability of finding polymorphism 
-6llA in PNTM was higher than in controls (OR=8.4, 
CI 95%=2.4-29.4) but not different than in DNTM 
(OR=1.3, CI 95%=0.1-14). The inferred haplotypes 
also showed a skewed distribution: DNTM vs. controls, 
p=O.Ol; PNTM vs. controls, p=O.O006; and DNTM vs. 
PNTM, p =0.0013. 
1nterpretation:Tbe IFNGRl MPR is highly polymorphic 
and some of these polymorphisms are significantly 
associated with nontuberculous mycobacterial infections. 
This is the first study in which common genetic suscepti- 
bility factors have been associated with both disseminated 
and pulmonary NTM infections. 
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Background: The human toll-like receptor (TLR) family 
plays crucial roles in both the innate and adaptive 
immune systems, Among the 10 TLRs identified, TLR2 
mediates responses to Gram-positive bacteria, including 
mycobacteria. We sought functional polymorphisms in 
the promoter region of TLR2. 
Methods: Using direct sequencing of PCR fragments 
as well as PCR fragment sizing we found a highly 
polymorphic (GT)n dinucleotide repeat around 120 bp 
upstream of the TLR2 translational start site. We 
examined the distribution of each allele in normal donors 
of African (n=106), Caucasian (n=88) and Korean 
(n=98) descent. To further understand the functional 
implications of these polymorphisms, we fused the 1.5 kb 
of upstream TLR2 containing different lengths of GT 
repeat to luciferase and examined these in transient 
transfection under different stimulation conditions. 
Results: The numbers of GT repeats varied from 12 
to 28, with significant differences in allele distribution 
between African Americans and Caucasians (p =O.OOS) 
and between African Americans and Koreans 
(p=O.O003). The promoter activity of the longer alleles 
[(GT)n 2201 was significantly more inhibited by 200 
IUlml of interferon-y (p=O.O02) than shorter alleles, 
Interestingly, this inhibition was not observed with 100 
IUlml of GM-CSF. Genotypes consisting of [(GT)n 
1201 repeats were more prevalent in patients with 
disseminated nontuberculous mycobacterial infection 
(49%) than in normal controls (24%,p=O.O04). 
Interpretation: Given that TLR2 is critical in the human 
immune response against invading organisms, functional 
microsatellite polymorphisms in its promoter may play 
a role in the pathogenesis of infectious and inflammatory 
diseases. This particular TLR2 promoter polymorphism 
is significantly different according to race, appears to 
be disease associated, and is functionally important and 
discriminating in terms of in vitro response to interferon- 
y, a cytokine critical to the integrity of inflammation. 
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Epstein-Barr virus (EBV) is associated with a deadly 
complication in organ transplantation, the so-called 
posttransplant lymphoproliferative disorders (PTLD). 
Mismatched EBV-seronegative recipients and sero- 
positive donors represent an important risk factor. The 
management of PTLD is difficult and an interesting 
preventive strategy would be to immunize the recipients 
before transplantation.The peptide-based vaccination is 
advantageous because of the absence of genetic material 
and its easiness to be manufactured. Nevertheless human 
leukocyte antigen (HLA) polymorphism in humans is a 
major obstacle to consider. One of the critical aspects to 
design such vaccine is to select a synthetic peptide that 
would be restricted by common HLA alleles and then 
would be available for more individuals such as EBV- 
seronegative ones. 
Objectives: Our main objectives were to evaluate the 
capacity of a synthetic peptide corresponding to EBNA2 
to induce specific T cells in vitro, to determine which 
HLA alleles restricted this epitope, and finally to study 
the reactivity of the specific peptide-induced T cells. 
Methods: We obtained peripheral blood mononuclear 
cells (PBMCs) from ten healthy donors. Then using the 
peptide TVFYNIPPMPL, we induced all these donors to 
select the best responders by proliferation assays. Using 
specific antibodies and HLA-known cells lines, we 
attempted to determine the HLA alleles for this epitope. 
Finally, after positively selected CD4+ cells from the 
best reactive T cell lines, we measured by flowcytometry 
their capacity to inhibit B cell transformation. 
Results: EBV positive serology was confirmed for 6 out 
of the 10 donors. From these latter, 60% shows specific 
T cell response to EBNA2 peptide and these were 
mostly CD4+ T helpers. We found these T cells epitope 
HLA-DR restricted for 5 donors (HLA-DRl: -DR16, - 
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DR52 and -DR7) and HLA-DQ (-DQ2) for one donor. 
Finally we demonstrated that purified peptide-induced 
CD4+ from one donor could inhibit the growth of EBV- 
infected autologous B-cells in the early phase of trans- 
formation. 
Conclusion: This EBNA2 synthetic peptide is very 
promising to design an EBV vaccine for nonimmune 
individuals awaiting solid organ transplantation. 
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Background: Virus-virus interactions may influence 
the pathogenesis of defined human viral infections. 
Using the clinical setting of liver transplantation (LT), 
we investigated the potential role that P-herpesviruses 
may play in the course of HCV infection. 
Methods: In 93 consecutive HCV-infected patients 
followed for a mean of 32 months post-LT, the incidence 
of CMV, human herpesvirus (HHV) -6 and -7 replication 
(assessed by PCR on 6 weekly serum samples) and CMV 
disease were evaluated for their impact on HCV- 
induced cirrhosis, retransplantation or mortality (primary 
end point). HCV replication and recurrence of HCV- 
induced hepatitis and fibrosis (assessed at 16 and 
52 weeks post-LT) were evaluated as secondary end 
points. Statistical analysis was performed using fre- 
quency tables, Kaplan Meier estimation, and proportional 
hazards regression. 
Results: The primary end point developed in 28% of 
patients. Independent of other significant predictors, we 
observed that CMV (40/91 [35.2%]) but not HHV-6 and 
-7 reactivation, and CMV disease (23/93 [24.7%]) were 
associated with the primary end point (Risk Ratio [RR], 
1.003; 95% CI, 1.001-1.004; P=O.O02; and RR, 4.189; 
95% CI, 1.838-9.546; P=O.OOl, respectively). Early CMV 
reactivation was strongly associated with mortality 
(8132 [25%] vs O/59 [O%]; PcO.001). CMV disease was 
also associated with higher fibrosis stage (mean ( SD, 
1.0*1.19 vs 0.49 (0.83;P=O.O4), modified hepatitis activity 
index (mean+SD, 4.1723.07 vs 2.96k2.42; P=O.O9), 
and plasma HCV RNA level (mean&SD, 5571250.47 
vEq/ml vs 36.17k46.95 vEq/ml; P=O.O7) at 16 weeks 
post-LT. 
Conclusion: Using the human model of LT, our study 
demonstrates that the pathogenesis of HCV is strongly 
and independently influenced by its interaction with 
CMV but not HHV-6 and -7. The lack of association 
between HCV and the other P-herpesviruses implies 
that the impact of CMV on HCV may be mediated by a 
direct HCV-CMV interaction that is beyond immuno- 
modulation. Importantly, it is observed that even low 
level CMV replication that does not evolve into clinical 
disease influences HCV outcome. Thus, aggressive CMV 
prevention may positively influence the clinical outcome 
of HCV-infected LT patients. 
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Background: XLP is an inherited immunodeficiency 
caused by SAP mutations. XLP often manifests itself 
as fulminant or fatal infectious mononucleosis after 
primary EBV infection; however, EBV is apparently 
unrelated to development of lymphoma or dysgamma- 
globulinemia, other major manifestations of XLI? Thus, 
how this virus involves the pathogenesis of XLP remains 
obscure. We experienced a patient with XLP who did not 
acquire any serious condition after primary EBV 
infection but eventually developed virus-associated 
hemophagocytic syndrome (VAHS) and malignant lym- 
phoma (ML) upon reactivation of EBV. 
Case Report: A 12-year-old boy presented with a 16-day 
history of fever and lumbago. Both the patient and his 9 
year old brother have been known to have hypogamma- 
globulinemia of unknown etiology, and were seropositive 
to EBV with uneventful past medical histories, except 
for several episodes of otitis media and an episode of 
pneumonia in the patient. Abdominal CT revealed para- 
aortic and pelvic lymphadenopathy. Open biopsy of the 
lymph nodes was performed, which showed necrotic 
tissue with no malignant cells. He did not respond anti- 
biotics, and subsequently VAHS was diagnosed. Despite 
intensive therapy including plasma exchange, immuno- 
suppressants and VP16, he deteriorated with develop- 
ment of multiple novel nodular lesions in lungs and 
bilateral pleural effusions, and died from multiple organ 
failure. Cytological analysis of pleural fluid was com- 
patible to malignant transformation. 
Immunologic Studies: Intracellular staining of SAP 
protein showed decreased SAP expression in T cells 
derived from these brothers. Direct sequencing revealed 
missense mutation S34G in their SAP genes. Plasma 
EBV load in the patient, determined by real-time PCR, 
was undetectable on admission, but markedly increased 
to 2.2~10~ copies/ml when he developed VAHS. In 
striking contrast, EBV-specific CTL was barely detect- 
able by MHC-peptide tetramer method. 
Conclusions: Despite impaired EBV-specific immunity, 
primary EBV infection in the patient, and also in his 
brother, appeared insignificant. Nevertheless, he ulti- 
mately developed such serious EBV-associated diseases 
as VAHS and ML. Thus, role of EBV infection in the 
pathogenesis of XLP may be complex. 
